Table 2.
Control Group, Randomization, and Masking of Recent Myopia Control Trials
| Author, Year | Intervention | Control | Randomization | Stratification | Masking | Study Length, y | Rebound Assessment |
|---|---|---|---|---|---|---|---|
| Bao et al. 2022101 | Spectacles (highly aspherical lenslets or slightly aspherical lenslets) | Spectacle (SV) | Y | N | Y | 2 | N |
| Chamberlain et al. 2022103 | SCL (concentric dual zone) | SCL (SV) | Y† | N | Y | 6† | Y (planned) |
| Chan et al. 2022108 | 0.01% atropine | Vehicle drop | Y | N | Y | 1.5 | N |
| Chuang et al. 2021109 | 0.05% atropine (concentration increased if >0.50 six-month progression) | N | N | N | N | 10 | N |
| Cui et al. 2021110 | 0.02% or 0.01% atropine | No treatment Self-selected |
Y/N (if self-selected atropine, randomized to 0.01% or 0.02%) | N | Y (if in an atropine arm) | 2 | N |
| Fu et al. 2021111 | 0.01% or 0.02% atropine | N | Y (to 0.01% or 0.02% atropine) | N | Y | 1 | N |
| Han et al. 2021125 | Auricular acupressure | No treatment | Y | N | Y (examiner only, not participant) | 1 | N |
| Hieda et al. 2021104 | SCL (multifocal) | SCL (SV) | Y | Y (adaptive randomization) | Y | 2 | N |
| Hieda et al. 2021112 | 0.01% atropine | Vehicle drop | Y | Y | Y | 2 | N |
| Jakobsen and Moller 2022107 | OK | Spectacle (SV) | Y | N | N | 1.5 | N |
| Jiang et al. 202274 | Low-level red light therapy | No treatment | Y | N | Y (examiner only, not participant) | 1 | N |
| Jones et al. 2022119 | 0.01% atropine with multifocal SCL | Historical controls (multifocal SCL group and SV SCL group) | N | N | N | 3 | N |
| Kong et al. 2021120 | 0.01% atropine plus auricular acupoint stimulation | 0.01% atropine | Y | Y | Y (examiner only, not participant) | 0.5 | N |
| Lam et al. 202198 | Spectacle (novel plus powered multiple segments) | Historical controls | Y | N | Y | 2ǂ (original control group followed 1 year on treatment) | N |
| Mori et al. 202182 | Violet light transmitting spectacles | Spectacle (SV) | Y | Y | Y | 2 | N |
| Moriche-Carretero et al. 2021113 | 0.01% atropine | No treatment | Y | N | N | 2 | N |
| Prousali et al. 2022102 | Part-time spectacle SV | Full-time spectacle SV | Y | N | N | 1 | N |
| Rappon et al. 202299 | Spectacles (two novel diffusion optics patterns) | Spectacle (SV with tint) | Y | Y | Y | 3 (reported 1-year results) | N |
| Ruiz-Pomeda et al. 2021105 | SCL (concentric dual zone) | Spectacle (SV) | Y | Y | N | 3 | Y (last year of study) |
| Saxena et al. 2021114 | 0.01% atropine | Vehicle drop | Y | N | Y | 1 | N |
| Shen et al. 2022106 | SCL (extended depth of focus) | SCL (SV; contralateral eye) | Y | N | Y | 1 | N |
| Wang et al. 2022115 | 0.02% or 0.01% atropine | No treatment | Y (to 0.01% or 0.02% only if chose atropine instead of spectacles) | N | Y (only in atropine arms) | 2 | N |
| Weng et al. 2022 117 | SCL (extended depth of focus and concentric dual zone) | SCL (SV; contralateral eye) | Y | N | Y | 1 | N |
| Yam et al. 2022116 | Atropine (0.01%, 0.025%, 0.05%) | Vehicle drop (year 1 only) | Y | Y | Y | 3 | Y (study year 3, half of each group) |
| Yuan et al. 2021118 | ortho-k with 0.01% Atropine | ortho-k with vehicle drop | Y | Y | Y | 2 | N |
| Zhu et al. 2022100 | Customized PALs | Spectacle (SV) | Y | N | Y | 2 | N |
†
Followed for an additional period after ending randomization.
ǂ
Randomized first 2 years, then all wore intervention lenses for an additional year with original control group compared to historical control group matched on age and refractive error.